OMS721 Granted Fast Track Designation for Atypical Hemolytic Uremic Syndrome
Omeros announced that the Food and Drug Administration (FDA) granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS).
Omeros is currently evaluating OMS721 in a Phase 2 clinical trial for the treatment of aHUS and other thrombotic microangiopathies (TMAs). Earlier this year, Omeros announced positive data from the Phase 2 trial and commencement of an investigator-requested compassionate use program. The Phase 2 clinical trial evaluating OMS721 in the treatment of TMAs, including aHUS, thrombotic thrombocytopenic purpura and human stem cell transplant-related TMAs, is ongoing.
OMS721 is a human monoclonal antibody that targets mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target involved in activation of the complement system.
For more information call (206) 676-5000 or visit Omeros.com.